Zydus Lifesciences gets USFDA Nod for Skincare Topical product

Zydus Life to purchase LiqMeds Group for Rs 689 Crore

Zydus Lifesciences Gets USFDA Nod for Skincare Topical Product

In a significant development for the pharmaceutical industry, Zydus Lifesciences proudly announced its recent achievement of obtaining final approval, the USFDA nod, from the United States Food and Drug Administration (USFDA) for an innovative skincare topical product aimed at combating acne. This latest addition to their product portfolio, the Clindamycin Phosphate Gel USP, is set to make a substantial impact on the treatment of acne in the United States.

The regulatory filing issued by Zydus Lifesciences reads, “We are pleased to announce the reception of final approval from the USFDA for our Clindamycin Phosphate Gel USP. Clindamycin, a potent antibiotic, functions by inhibiting bacterial growth and reducing the number of acne lesions. Recent IQVIA MAT data from July 2023 indicates annual sales of USD 37 million in the United States for this product.”

Manufacturing of this groundbreaking medication will take place at Zydus Lifesciences’ state-of-the-art production facility located in Changodar, Ahmedabad. This facility is renowned for its adherence to the highest standards of quality and safety, ensuring that patients receive the best possible skincare treatment.

Zydus Lifesciences is a dynamic player in the pharmaceutical arena, dedicated to the development, manufacturing, and marketing of a diverse range of products, encompassing Active Pharmaceutical Ingredients (API) and generic drugs. This latest achievement aligns perfectly with the company’s commitment to improving the quality of life for people around the world.

As evidence of its ongoing success, Zydus Lifesciences reported impressive financial results in its quarterly report for the April-June quarter. The company experienced a remarkable 96.87% year-over-year increase in net profit, reaching an impressive Rs 1,134 crore. Furthermore, its revenue from operations showed strong growth, surging by 26.19% year-over-year to reach Rs 5,140 crore.

This USFDA approval not only marks a significant milestone for Zydus Lifesciences but also offers hope to countless individuals suffering from acne. With the introduction of the Clindamycin Phosphate Gel USP, a powerful solution for acne management, Zydus Lifesciences continues to make strides in improving healthcare and enhancing the quality of life for people worldwide. Stay tuned for more updates as this groundbreaking skincare product becomes available to consumers in the United States and beyond.

About Zydus Lifesciences:

Zydus Lifesciences Limited functions as a comprehensive lifesciences enterprise, specializing in the production and distribution of a wide array of healthcare solutions. These encompass formulations, active pharmaceutical ingredients, vaccines, diagnostic tools, health and dietetic products, animal healthcare offerings, as well as cosmeceuticals.

For more of the Latest News, Click Here

Leave a Reply

Your email address will not be published. Required fields are marked *